Spots Global Cancer Trial Database for MRI-guided Lateral Lymph Node Dissection in Rectal Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: MRI-guided Lateral Lymph Node Dissection in Rectal Cancer

Official Title: MAgnetic Resonance Imaging Guided LAteral Lymph Node Dissection in Lower REctal Cancer - A Multicenter, Prospective, Registry Study (MALAREC)

Study ID: NCT04850027

Conditions

Rectal Cancer

Interventions

TME+Lateral lymph node dissection.

Study Description

Brief Summary: To investigate the oncological outcome of lateral lymph node dissection in low rectal cancer based on MRI

Detailed Description: Our study design is a multicenter, prospective, registry study. We would enroll 268 patients with lower rectal cancer whose preoperative MRI showed laterally lymph node diameter ≥ 5mm. The postoperative adjuvant chemoradiotherapy is determined by the pathological results. For patients of stage II and patients of stage III with unfavorable histologic features, six months of adjuvant chemotherapy of fluorouracil-based regimen with radiotherapy of 45.0 \~ 50.5 Gy are recommended. The postoperative examination should be performed every three months in the first two years and every six months in the following three years. Our study is expected to last five years, of which two years for recruiting patients, three years for follow-up.